Intellia Therapeutics (NTLA) Current Deferred Revenue (2015 - 2026)
Intellia Therapeutics (NTLA) posted quarterly Current Deferred Revenue of $630000.0 for Q1 2026, down 98.14% year-over-year from $33.8 million in Q1 2025, and down 91.36% quarter-over-quarter from $7.3 million in Q4 2025.
Intellia Therapeutics (NTLA) Current Deferred Revenue (2015 - 2026) Analysis & Trends
Intellia Therapeutics (NTLA) has reported Current Deferred Revenue for 12 consecutive years, with $630000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Current Deferred Revenue fell 98.14% year-over-year to $630000.0; the TTM figure through Mar 2026 stood at $630000.0 (down 98.14% YoY), while the FY2025 annual figure was $7.3 million, down 81.27% from the prior year.
- Current Deferred Revenue retreated to $630000.0 in Q1 2026 per NTLA's latest filing, from $7.3 million in the prior quarter.
- Across five years, Current Deferred Revenue topped out at $113.2 million in Q1 2022 and bottomed at $630000.0 in Q1 2026.
- Historically, Current Deferred Revenue has averaged $47.7 million across 5 years, with a median of $44.8 million in 2024.
- Annual changes were most pronounced in 2024 — Current Deferred Revenue jumped 71.73% — and 2026, when it sank 98.14%.
- Intellia Therapeutics' Current Deferred Revenue stood at $63.8 million in 2022, then decreased by 4.36% to $61.0 million in 2023, then plunged by 36.19% to $38.9 million in 2024, then tumbled by 81.27% to $7.3 million in 2025, then sank by 91.36% to $630000.0 in 2026.
- Business Quant data shows NTLA's Current Deferred Revenue at $630000.0 in Q1 2026, $7.3 million in Q4 2025, and $24.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Intellia Therapeutics | 1.67 Bn | 1.67 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 630,000.00 |
| Dec 31, 2025 | 7.29 Mn |
| Sep 30, 2025 | 24.79 Mn |
| Jun 30, 2025 | 29.69 Mn |
| Mar 31, 2025 | 33.82 Mn |
| Dec 31, 2024 | 38.92 Mn |
| Sep 30, 2024 | 44.76 Mn |
| Jun 30, 2024 | 50.24 Mn |
| Mar 31, 2024 | 55.62 Mn |
| Dec 31, 2023 | 60.99 Mn |
| Sep 30, 2023 | 26.07 Mn |
| Jun 30, 2023 | 34.85 Mn |
| Mar 31, 2023 | 49.21 Mn |
| Dec 31, 2022 | 63.77 Mn |
| Sep 30, 2022 | 80.50 Mn |
| Jun 30, 2022 | 97.14 Mn |
| Mar 31, 2022 | 113.24 Mn |
| Dec 31, 2021 | 127.24 Mn |
| Sep 30, 2021 | 119.78 Mn |
| Jun 30, 2021 | 62.75 Mn |